Cellular Biomedicine Group today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC therapy for hepatocellular carcinoma , the most common type of liver cancer.
http://www.freshnews.com/news/835843/cellular-biomedicine-group-announces-completion-patient-enrollment-phase-i-clinical-tri
http://www.freshnews.com/news/835843/cellular-biomedicine-group-announces-completion-patient-enrollment-phase-i-clinical-tri
No comments:
Post a Comment